ArticleTheranostics2017
The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors.
Article in Theranostics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 60 citations in OpenAlex.
- Prognostic value of the dual-tracer PET score (NETPET) in neuroendocrine tumors with [European journal of nuclear medicine and molecular imaging · 2026Article
- Dual‑targeted radioligand therapy with [European journal of nuclear medicine and molecular imaging · 2026Article
- Clinical research analysis of [European journal of nuclear medicine and molecular imaging · 2026Article
- Kussmaul's Sign Provoked by Intracardiac Metastasis of Endometrial Neuroendocrine Tumor.The Kaohsiung journal of medical sciences · 2025Article
- [Imaging of pancreatic neuroendocrine tumors].Radiologie (Heidelberg, Germany) · 2024Article
- Advancements in Neuroendocrine Neoplasms: Imaging and Future Frontiers.Journal of clinical medicine · 2024Review
- Contemporary Approaches to the Surgical Management of Pancreatic Neuroendocrine Tumors.Cancers · 2024Review
- Evaluating Prognosis of Gastrointestinal Metastatic Neuroendocrine Tumors: Constructing a Novel Prognostic Nomogram Based on NETPET Score and Metabolic Parameters from PET/CT Imaging.Pharmaceuticals (Basel, Switzerland) · 2024Article
- PET/MRI imaging in neuroendocrine neoplasm.Abdominal radiology (New York) · 2023Review
- Diagnostic and prognostic value ofArchives of medical science : AMS · 2023Article
- Liver transplantation for malignant liver tumors.iLIVER · 2022Review
- Review
- Role of CombinedDiagnostics (Basel, Switzerland) · 2022Review
- How Many Times Can One Go Back to the Drawing Board before the Accurate Diagnosis and Surgical Treatment of Glucagonoma?Diagnostics (Basel, Switzerland) · 2022Article
- Dual-tracer PET/CT imaging to determine tumor heterogeneity in a patient with metastatic ACTH-secreting neuroendocrine neoplasm: A case report and literature review.Frontiers in endocrinology · 2022Review
- Perspectives on the diagnostic, predictive and prognostic markers of neuroendocrine neoplasms (Review).Experimental and therapeutic medicine · 2021Review
- Current update on imaging for pancreatic neuroendocrine neoplasms.World journal of clinical oncology · 2021Review
- Combination Therapies with PRRT.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Imaging of neuroendocrine tumors: A pictorial review of the clinical value of different imaging modalities.Reviews in endocrine & metabolic disorders · 2021Review
- Review
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine tumors (NET) are often metastatic at the time of diagnosis. Metastatic well-differentiated (G1/G2) NET may display a wide range of behaviors, ranging from indolent to aggressive, even within apparently homogeneous categories. Thus, selecting the optimal treatment strategy is a challenging task. Somatostatin receptor imaging (SRI) is the standard molecular imaging technique for well-differentiated NET. When performed with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.